153 related articles for article (PubMed ID: 10510383)
1. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain.
Penichet ML; Kang YS; Pardridge WM; Morrison SL; Shin SU
J Immunol; 1999 Oct; 163(8):4421-6. PubMed ID: 10510383
[TBL] [Abstract][Full Text] [Related]
2. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery.
Asai T; Trinh R; Ng PP; Penichet ML; Wims LA; Morrison SL
Biomol Eng; 2005 Feb; 21(6):145-55. PubMed ID: 15748688
[TBL] [Abstract][Full Text] [Related]
3. An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells.
Ng PP; Dela Cruz JS; Sorour DN; Stinebaugh JM; Shin SU; Shin DS; Morrison SL; Penichet ML
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10706-11. PubMed ID: 12149472
[TBL] [Abstract][Full Text] [Related]
4. Functional and pharmacokinetic properties of antibody-avidin fusion proteins.
Shin SU; Wu D; Ramanathan R; Pardridge WM; Morrison SL
J Immunol; 1997 May; 158(10):4797-804. PubMed ID: 9144494
[TBL] [Abstract][Full Text] [Related]
5. Drug targeting to the brain using avidin-biotin technology in the mouse; (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease).
Jeong Lee H; Pardridge WM
J Drug Target; 2000; 8(6):413-24. PubMed ID: 11328667
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor.
Kang YS; Bickel U; Pardridge WM
Drug Metab Dispos; 1994; 22(1):99-105. PubMed ID: 8149897
[TBL] [Abstract][Full Text] [Related]
7. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor.
Yoshikawa T; Pardridge WM
J Pharmacol Exp Ther; 1992 Nov; 263(2):897-903. PubMed ID: 1432704
[TBL] [Abstract][Full Text] [Related]
8. Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans.
Boado RJ; Zhang Y; Zhang Y; Xia CF; Wang Y; Pardridge WM
Bioconjug Chem; 2008 Mar; 19(3):731-9. PubMed ID: 18278853
[TBL] [Abstract][Full Text] [Related]
9. Targeting of biotinylated compounds to its target tissue using a low-density lipoprotein receptor-avidin fusion protein.
Lehtolainen P; Wirth T; Taskinen AK; Lehenkari P; Leppänen O; Lappalainen M; Pulkkanen K; Marttila A; Marjomäki V; Airenne KJ; Horton M; Kulomaa MS; Ylä-Herttuala S
Gene Ther; 2003 Dec; 10(25):2090-7. PubMed ID: 14595382
[TBL] [Abstract][Full Text] [Related]
10. Use of neutral avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate.
Kang YS; Pardridge WM
J Pharmacol Exp Ther; 1994 Apr; 269(1):344-50. PubMed ID: 8169841
[TBL] [Abstract][Full Text] [Related]
11. Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor.
Rodríguez JA; Helguera G; Daniels TR; Neacato II; López-Valdés HE; Charles AC; Penichet ML
J Control Release; 2007 Dec; 124(1-2):35-42. PubMed ID: 17884229
[TBL] [Abstract][Full Text] [Related]
12. An interaction between S*tag and S*protein derived from human ribonuclease 1 allows site-specific conjugation of an enzyme to an antibody for targeted drug delivery.
Asai T; Wims LA; Morrison SL
J Immunol Methods; 2005 Apr; 299(1-2):63-76. PubMed ID: 15914191
[TBL] [Abstract][Full Text] [Related]
13. Enhanced uptake of rsCD4 across the rodent and primate blood-brain barrier after conjugation to anti-transferrin receptor antibodies.
Walus LR; Pardridge WM; Starzyk RM; Friden PM
J Pharmacol Exp Ther; 1996 May; 277(2):1067-75. PubMed ID: 8627518
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
Wu D; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431
[TBL] [Abstract][Full Text] [Related]
15. Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells.
Daniels TR; Ng PP; Delgado T; Lynch MR; Schiller G; Helguera G; Penichet ML
Mol Cancer Ther; 2007 Nov; 6(11):2995-3008. PubMed ID: 18025284
[TBL] [Abstract][Full Text] [Related]
16. Brain delivery of biotinylated NGF bounded to an avidin-transferrin conjugate.
Li XB; Liao GS; Shu YY; Tang SX
J Nat Toxins; 2000 Feb; 9(1):73-83. PubMed ID: 10701183
[TBL] [Abstract][Full Text] [Related]
17. Stability of the disulfide bond in an avidin-biotin linked chimeric peptide during in vivo transcytosis through brain endothelial cells.
Kang YS; Voigt K; Bickel U
J Drug Target; 2000; 8(6):425-34. PubMed ID: 11328668
[TBL] [Abstract][Full Text] [Related]
18. Transferrin-antibody fusion proteins are effective in brain targeting.
Shin SU; Friden P; Moran M; Olson T; Kang YS; Pardridge WM; Morrison SL
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2820-4. PubMed ID: 7708731
[TBL] [Abstract][Full Text] [Related]
19. Mapping IgG epitopes bound by rheumatoid factors from immunized controls identifies disease-specific rheumatoid factors produced by patients with rheumatoid arthritis.
Bonagura VR; Agostino N; Børretzen M; Thompson KM; Natvig JB; Morrison SL
J Immunol; 1998 Mar; 160(5):2496-505. PubMed ID: 9498795
[TBL] [Abstract][Full Text] [Related]
20. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo.
Pardridge WM; Buciak JL; Friden PM
J Pharmacol Exp Ther; 1991 Oct; 259(1):66-70. PubMed ID: 1920136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
